accident'. Rather, a mechanism is proposed that could activate transcription of numerous genes in spermatids. If a gene is transcribed and its protein accumulates in spermatids, it is very possible that the protein will function there.
Essay Two hundred years of vaccination Derrick Baxby
In a world in which infectious diseases seem once again to be on the increase, it is perhaps fitting that 1996 sees various events to commemorate the first documented smallpox vaccination, performed by Edward Jenner on May 14 1796 [1] . This article will consider Jenner's claim to fame and a few of the key events in the 200 years of vaccination that have followed his pioneering experiment.
Jenner has always been a controversial figure who polarized opinion, with even his supporters divided on whether he was a genius or a simple country doctor. That he preferred life in Gloucestershire rather than London is certain. Nevertheless, by 1796 he was a wellrespected doctor-scientist, trained in London by John Hunter, with a general practice in Berkeley and a consultant practice in fashionable Cheltenham [2] .
Jenner the naturalist
Although Jenner's name is inextricably linked with vaccination he should still have been remembered, particularly by zoologists, for his studies on bird behaviour, even if he had not developed smallpox vaccine. It had long been known that the female cuckoo lays her eggs in the nests of other birds. It was not known, however, how the eggs and nestlings of the foster parents were disposed of; the foster parents and the female cuckoo were variously thought to be responsible. In 1787, Jenner observed that it was the newly hatched cuckoo which ejected the eggs and nestlings of its foster parents; for this work he was made a Fellow of the Royal Society (FRS) in 1789 [2, 3] .
In these studies, Jenner was not content just to report observations: he tried to determine how and why the observed events occurred. For example, he described the anatomical modification to the back of the newly hatched cuckoo which facilitates its murderous activities, and which disappears within about 12 days of hatching. He also reasoned that the adult cuckoo laid its eggs in other birds' nests because it only stayed in Britain for about 11 weeks and would not have enough time to rear its young before it departed. At a time when some still believed that birds hibernated, he showed that the impulse to migrate was connected with changes in the reproductive organs and not due to climate or availability of food. With this analytical attitude it was perhaps inevitable that Jenner would become interested in the control of disease.
Jenner and smallpox
In the 18th century, smallpox was a major killer, leaving visible scars on many survivors. Its importance can perhaps most easily be appreciated by showing its effects on the family of King Charles I (Fig. 1) . Attempts had been made for many years to control smallpox by 'variolation', the deliberate inoculation of smallpox virus into the skin in the hope that a mild but immunizing disease would result. There was a risk of severe smallpox for the inoculated and their contacts, however.
Jenner, an experienced variolator, became interested in the current folk lore concerning cowpox and smallpox in the late 1770s. The idea was that those individuals -traditionally milkmaids -who had recovered from cowpox could not later contract smallpox. Cowpox was a mild localized infection and Jenner collected circumstantial information that seemed to confirm the milkmaids' story. On May 14 1796, just before his 47th birthday, he inoculated 8 year-old James Phipps at two sites with material taken from the hand of a milkmaid, Sarah Nelmes (Fig. 2) . The lesions developed uneventfully and healed, and six weeks later Phipps was inoculated with smallpox, which had no effect. Although probably not the first to try this experiment, Jenner was the first to report it.
Jenner showed this information to the Royal Society but was advised to do more work, which he did in 1798 (see Fig. 3 ). The value of this small trial was that it showed that the material (soon to be called 'vaccine', from the Latin vacca, a cow) could be transmitted from a pustule on one arm to another arm without altering its effects, thus reducing reliance on the cow as a source of material. He published his results in his now famous Inquiry of 1798 [4] .
The number of people vaccinated by Jenner was small and the duration of immunity unknown. As a result, Jenner caused some controversy with the claim that his vaccine was safe and induced lifelong immunity. Obviously, more trials and long-term follow up studies were needed to establish these claims, and eventually the importance of revaccination was recognized.
Although many influential authorities saw the value of vaccination and Jenner's role in its introduction, there was some opposition to vaccination and/or Jenner. Variolators saw the loss of a lucrative monopoly. Others claimed that their extended trials established the value of vaccination, and although there is some truth in this, such work could only build on Jenner's foundations.
One very important feature of Jenner's work was the distinction he drew between 'true' and 'spurious' cowpox. The former gave the expected result: a mild localized infection which produced immunity to smallpox. Spurious cowpox produced untoward effects and/or no immunity and Jenner recognized distinct varieties. In modern terms, these would include other bovine diseases infectious for humans, or material from an old cowpox lesion which no longer contained infective virus and was contaminated with pathogenic bacteria. Although the excuse of spurious cowpox was used to explain away genuine vaccine failures and the need for revaccination, Jenner's ability to grasp and explain this concept many years before the provision of laboratory facilities to support it was remarkable.
Some early vaccines, particularly those introduced by George Pearson, and developed at the London Smallpox Hospital, contained smallpox virus due to initial confusion over the appearance of cowpox and inoculated smallpox. Consequently, some claimed that vaccine was simply modified smallpox virus, and that Jenner had introduced no new principle. If true, this would severely damage Jenner's reputation -but vaccines were soon introduced from cowpox in circumstances where no contamination could occur, and modern studies have confirmed earlier views that smallpox vaccine could not be derived from smallpox virus [2] .
Jenner's claim was initially based on few vaccinations and he erred in his belief that immunity was lifelong. Nevertheless, his use of an animal virus to induce immunity to smallpox marks a distinct break with previous practice. This, together with his analysis of true and spurious cowpox, without which vaccination could not have been developed, justifies the credit he has been given [1, 2, 5] .
Vaccination against smallpox became established world-widethough not without opposition -and laid the foundation for the control and eventual eradication of smallpox [5] . Although vaccination reduced the overall incidence of smallpox, eradication was not achieved simply by mass vaccination. A much more active strategy was adopted: rewards were offered and trained workers sought out cases. Once detected, cases and contacts were isolated until they were no longer infectious. This surveillance-containment strategy effectively broke the chain of transmission, often without the need for mass vaccination, and proved the key to eradication [5] .
Into the modern era
The introduction of smallpox vaccine was not immediately followed by the development of other vaccines, for simple but obvious reasons. Firstly, by the 18th century, smallpox could be diagnosed clinically, enabling assessment of the effects of the vaccine; the diagnosis of most other infections was much less certain. Secondly, until Pasteur and Koch developed methods for the cultivation of micro-organisms, only clinical material could be used as vaccine. Smallpox and cowpox were ideal in this respect, but suitable clinical material was not easily available for other infections.
By 1881 Pasteur had developed vaccines for anthrax and chicken cholera. These were important because they showed how microorganisms could be attenuated in vitro, and that immunization could be extended to other infections including those in animals. Until 1881, vaccine and vaccination had only one meaning, but Pasteur proposed that, to honour Jenner, the terms should include all immunization procedures. In 1885, Pasteur set two more important precedents with his rabies vaccine: a vaccine for both animals and humans, and the use of a vaccine for post-exposure prophylaxis.
Although typhoid vaccines containing killed whole organisms were used during the first world war, their effectiveness was doubted and the next major vaccine, for tuberculosis, was developed by Calmette and Guérin in 1921-1923. Appropriately, their vaccine (BCG) was developed from a bovine tuberculosis strain. The importance of anti-toxin immunity was appreciated early in the 20th century, and by the 1920s toxoid vaccines (inactivated toxin) were introduced for diphtheria and tetanus. Effective virus vaccines for such diseases as poliomyelitis, measles, and rubella were developed in the 1950s-1960s, based on the important cell culture studies by John Enders and colleagues [1, 6] .
Pioneer immunologists debated the importance of cellular immunity, as championed by Metchnikoff, and humoral immunity, first expounded by Nuttall and Flugge. At first, work on toxin-antitoxin reactions indicated that humoral immunity, involving antigen-antibody reactions, was particularly important. Subsequently the importance of cell-mediated immunity was appreciated, as was the fact that different populations of white blood cells are involved in the two arms of the immune system. Cellmediated immunity is mediated via T lymphocytes, whereas B lymphocytes produce the antibodies involved in humoral immunity.
Concurrently, protein chemists and immunologists investigated the different classes of immunoglobulins, in particular differences between circulating antibodies (IgM and IgG) and those secreted at mucosal surfaces (IgA). Now it was possible to explain the success and failures of vaccines, and to predict vaccine requirements for particular infections [1, 7] .
Modern vaccines
There are real or potential difficulties with all vaccines. There may be problems with attenuation of live vaccines, with possible risks for vaccinees or their contacts. With noninfectious vaccines, there may be problems in identifying and preserving the immunogenic components and of ensuring correct presentation of the antigens so that the appropriate immune response is stimulated. With all vaccines, there are potential problems of delivery and storage, particularly in tropical climates. In this respect, the WHO Programme of Expanded Immunization is building on experience gained during the Smallpox Eradication Campaign to facilitate widespread use of vaccines. There are still problems caused by, for example, influenza virus, human immunodeficiency virus (HIV), and various respiratory and enteric pathogens which have variable and/or multiple serotypes, and also by malaria, but progress is being made. Various vaccines are being tested against typhoid, cholera and rotavirus gastroenteritis [1, 8] , and considerable attention is being paid to a synthetic subunit vaccine for malaria [9] . Various HIV vaccines are being developed, and the recent isolation of apparently naturally attenuated mutants of HIV which lack the nef gene suggests they may be developed into attenuated vaccines [10] .
Recombinant DNA technology has already made a considerable impact through the successful yeast recombinant hepatitis B vaccine [1, 11] , and it is appropriate that smallpox vaccine still has a role to play. Infectious vaccinia recombinant vaccines which express the immunogenic glycoprotein of rabies virus are proving very successful in Europe for oral immunization of foxes, the principal wildlife reservoir of rabies [12] . Although there are reservations about the widespread use of recombinant vaccinia vaccines, particularly in humans, the technology is being transferred to other poxviruses. Candidate mammalian vaccines are being developed using recombinant canarypox vectors which induce good immune responses although they do not replicate in mammalian cells [1, 13] .
Considerable interest is also being shown in 'DNA vaccines' [14] . These comprise the appropriate gene inserted into a plasmid carrier which, when injected into the body, is taken up by host cells. The viral gene is expressed and the antigen preferentially stimulates cellmediated immunity. By appropriate use of reverse transcriptase, recombinant DNA vaccines are being developed for RNA virus infections, particularly influenza.
Jenner's pioneer work on smallpox vaccine was not immediately extended to the control of other infections. However, vaccines have made a significant impact in developed countries, through the control of, for example, measles, diphtheria, tetanus and polio, and the widespread use of these and other vaccines in developing countries should have similar effects. There are still problems with infectious diseases, however, and current vaccine research may help to solve these. Increasing concern about antibiotic-resistant bacteria and the slow rate of development of antiviral drugs emphasizes the 'truism' that prevention is better than cure; the ultimate goal should be eradication. This has been achieved for smallpox [5] , and is achievable for polio by the year 2000 by mass vaccination [15] .
